These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33209190)

  • 21. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research and development in drug innovation: reflections from the 2013 bioeconomy conference in China, lessons learned and future perspectives.
    Liu C; Constantinides PP; Li Y
    Acta Pharm Sin B; 2014 Apr; 4(2):112-9. PubMed ID: 26579372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
    Lo TF; Hsieh CR
    J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use.
    Daniel GW; Cazé A; Romine MH; Audibert C; Leff JS; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):319-27. PubMed ID: 25646113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining "innovativeness" in drug development: a systematic review.
    Kesselheim AS; Wang B; Avorn J
    Clin Pharmacol Ther; 2013 Sep; 94(3):336-48. PubMed ID: 23722626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rise of micropharma.
    Barden CJ; Weaver DF
    Drug Discov Today; 2010 Feb; 15(3-4):84-7. PubMed ID: 19837185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multifaceted Perspective of Pharmaceutical Innovation: A Consideration of the Regulatory Role.
    Robberson M; Breder CD
    Ther Innov Regul Sci; 2021 Mar; 55(2):262-269. PubMed ID: 32869110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drugs and new molecular entities in dermatology.
    Eaglstein WH; Corcoran G
    Arch Dermatol; 2011 May; 147(5):568-72. PubMed ID: 21576576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2017 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2018 Aug; 23(8):1469-1473. PubMed ID: 29751111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition.
    Evens RP
    AAPS J; 2016 Jan; 18(1):281-5. PubMed ID: 26475480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.
    Outterson K; Powers JH; Seoane-Vazquez E; Rodriguez-Monguio R; Kesselheim AS
    J Law Med Ethics; 2013; 41(3):688-96. PubMed ID: 24088160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open innovation in early drug discovery: roadmaps and roadblocks.
    Reichman M; Simpson PB
    Drug Discov Today; 2016 May; 21(5):779-88. PubMed ID: 26743597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A measure of productivity and innovation in the pharmaceutical industry 2011-2015.
    Harrison R
    Drugs Today (Barc); 2016 Nov; 52(11):627-633. PubMed ID: 28112281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011.
    Lichtenberg FR
    Int J Health Econ Manag; 2015 Sep; 15(3):339-359. PubMed ID: 27878681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.